Furthermore, we explore whether DIRAS3 regulated the RAS/ERK pathway in NSCLC cells, and our findings suggest that DIRAS3 may inhibit NSCLC cell progression by modulating the RAS/ERK pathway. Here, DIRAS3 is linked to non-small cell lung carcinoma.